Showing results (651-660 of 690) with videos related to

Sort By:
Pageof 69
Emerging Infectious Diseases|November 2, 2022
Serologic Surveillance for SARS-CoV-2 Infection among Wild Rodents, EuropeVincent Bourret, Lara Dutra, Hussein Alburkat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 3, 2024
Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low-Back Pain With Modic Type 1 Changes: A Randomized Controlled TrialElisabeth Gjefsen, Lars C Bråten, Erica Ponzi, et al.
Nature Communications|September 13, 2024
Emerging multiscale insights on microbial carbon use efficiency in the land carbon cycleXianjin He, Elsa Abs, Steven D Allison, et al.
Frontiers in Immunology|October 1, 2025
Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptidesDeAnna J Friedman-Klabanoff, Travis L Jensen, Kirsten E Lyke, et al.
Jornal Brasileiro De Nefrologia|March 19, 2024
COVID-19 Computed tomography patterns in renal replacement therapy patientsGabriel Assis Lopes do Carmo, Mariana Paiva Oliveira, Anna Luiza Lino Campos, et al.
The Lancet. Rheumatology|November 23, 2022
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort studyKristin H Bjørlykke, Hilde S Ørbo, Anne T Tveter, et al.
Iscience|April 28, 2022
A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathwayNane C Kuznik, Valeria Solozobova, Irene I Lee, et al.
Nature Communications|August 15, 2022
Process-oriented analysis of dominant sources of uncertainty in the land carbon sinkMichael O'Sullivan, Pierre Friedlingstein, Stephen Sitch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 4, 2022
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive TherapySilje W Syversen, Ingrid Jyssum, Anne T Tveter, et al.
The Lancet. Rheumatology|January 3, 2022
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort studyIngrid Jyssum, Hassen Kared, Trung T Tran, et al.
Pageof 69